コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 of the 5-lipoxygenase metabolite, 5-HETE (5-hydroxyeicosatetraenoic acid).
2 can be reduced to the eicosanoid 12-HETE (12-hydroxyeicosatetraenoic acid).
3 15-lipoxygenase pathway, predominantly to 15-hydroxyeicosatetraenoic acid.
4 se, which converts arachidonic acid to 15(S)-hydroxyeicosatetraenoic acid.
5 oxylase products (+/-)-15-, (+/-)-19-, or 20-hydroxyeicosatetraenoic acid.
6 r of omega-hydroxylase, which synthesizes 20-hydroxyeicosatetraenoic acid.
7 in so doing up-regulate the production of 15-hydroxyeicosatetraenoic acid.
8 also catalyze the formation of a variety of hydroxyeicosatetraenoic acids.
9 ially inhibited by exogenous 12(S)- or 15(S)-hydroxyeicosatetraenoic acids.
10 glandins, plus smaller amounts of 11- and 15-hydroxyeicosatetraenoic acids.
11 hway producing epoxyeicosatrienoic acids and hydroxyeicosatetraenoic acids.
12 leukotrienes, epoxyeicosatrienoic acids, and hydroxyeicosatetraenoic acids.
13 cluding epoxyeicosatrienoic acids (EETs) and hydroxyeicosatetraenoic acids.
14 xyeicosatetraenoic acid (15-HETE) and 11-(R)-hydroxyeicosatetraenoic acid (11-HETE), whereas acetylat
16 nd that the 12/15-lipoxygenase product 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE) increased AT1R
18 ed whether thrombin or the eicosanoid, 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE), could activat
19 ic acid metabolite of 12-lipoxygenase, 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE), not only medi
23 etabolized by 12-lipoxygenase (12-LOX) to 12-hydroxyeicosatetraenoic acid (12-HETE) and has an import
24 homogenates from disrupted cells produced 12-hydroxyeicosatetraenoic acid (12-HETE) and minor amounts
27 tauro-beta-muricholate, taurocholate and 12-hydroxyeicosatetraenoic acid (12-HETE) were detected in
28 xyoctadecadienoic acid (13-HODE) and 12-( S)-hydroxyeicosatetraenoic acid (12-HETE), also affect subs
29 tion of the allosteric effector molecule, 12-hydroxyeicosatetraenoic acid (12-HETE), indicating a tun
30 an arachidonate 12-lipoxygenase (ALOX12)-12-hydroxyeicosatetraenoic acid (12-HETE)-G-protein-coupled
32 se-derived arachidonate metabolite and 12(R)-hydroxyeicosatetraenoic acid (12[R]-HETE) is formed by a
33 NPD1, PEDF+DHA, lipoxin A4 (LXA4), 12- or 15-hydroxyeicosatetraenoic acid (12[S] or 15[S]-HETE), and
36 creased levels of the 12/15-LO product 12(S)-hydroxyeicosatetraenoic acid [12(S)-HETE] and also 12/15
37 ceptor 31 (GPR31) as the high-affinity 12(S)-hydroxyeicosatetraenoic acid [12(S)-HETE] receptor (12-H
38 d, other cP450 arachidonate metabolites (12R-hydroxyeicosatetraenoic acid (12R-HETE), 14,15-dihydroxy
39 the unusual arachidonic acid metabolite 12R-hydroxyeicosatetraenoic acid (12R-HETE), a product of th
41 s in levels of urinary 12/15LO products, 12S-hydroxyeicosatetraenoic acid (12S-HETE) and 13S-hydroxyo
42 lated IK, and the 12-LO metabolite of AA 12S-hydroxyeicosatetraenoic acid (12S-HETE) stimulated IK.
43 To understand the mechanisms by which 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE) activates Rac1
44 To understand the mechanisms by which 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE) activates sign
45 on of its arachidonic acid metabolites 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE) and 12(S)-hydr
46 is able to blunt PDGF-induced ROS and 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE) production, in
47 rgeted lipidomics approach showed that 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE) was the major
48 t with the 15-lipoxygenase metabolite, 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE), followed by E
49 5-LOX1 metabolite of arachidonic acid, 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE), on vascular s
53 of matrix metalloproteinases (MMPs) in 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE)-induced angiog
54 erstand the molecular basis underlying 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE)-induced angiog
56 rtly involves the 15-LOX-2 promoter and 15-S-hydroxyeicosatetraenoic acid (15-(S)-HETE), a product of
57 is essentially a lipoxygenase, making 15-(R)-hydroxyeicosatetraenoic acid (15-HETE) and 11-(R)-hydrox
58 12/15-Lipoxygenase (12/15-LO) produces 15-hydroxyeicosatetraenoic acid (15-HETE) and 13-hydroxyoct
59 tes two products in nearly equal amounts: 15-hydroxyeicosatetraenoic acid (15-HETE) and 15-ketoeicosa
60 yclooxygenase-2-derived lipoxin precursor 15-hydroxyeicosatetraenoic acid (15-HETE) in esterified for
61 the ability of one of these metabolites, 15-hydroxyeicosatetraenoic acid (15-HETE), to regulate the
64 oxygenase (soybean lipoxidase), or [U-14C]15-hydroxyeicosatetraenoic acid (15-HPETE) and analyzed by
66 o understand the mechanisms underlying 15(S)-hydroxyeicosatetraenoic acid [15(S)-HETE]-induced angiog
67 Epithelial 15LO1 generates intracellular 15-hydroxyeicosatetraenoic acid (15HETE) conjugated to phos
68 ock prostaglandin biosynthesis, and give 15R-hydroxyeicosatetraenoic acid (15R-HETE) as the only prod
69 etory cells and benign prostate produces 15S-hydroxyeicosatetraenoic acid (15S-HETE) from exogenous a
70 bility of benign prostate tissue to form 15S-hydroxyeicosatetraenoic acid (15S-HETE) from exogenous a
72 upregulation of CYP4A and an increase in 20-hydroxyeicosatetraenoic acid (20-HETE) and Nox oxidases.
73 n of omega-hydroxylase, and the efflux of 20-hydroxyeicosatetraenoic acid (20-HETE) from the isolated
75 amily (CYP4A) convert arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE) in blood vessels
76 ood pressure (BP)), and exhibit increased 20-hydroxyeicosatetraenoic acid (20-HETE) in kidney and uri
83 dizes endogenous arachidonic acid (AA) to 20-hydroxyeicosatetraenoic acid (20-HETE), a metabolite wit
84 a-hydroxylase catalyzing the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), a potent constri
85 me P450 4A enzymes (P450 4A) and produce 20- hydroxyeicosatetraenoic acid (20-HETE), a potent constri
86 roinflammatory hepatic prostaglandins and 20-hydroxyeicosatetraenoic acid (20-HETE), a potent vasocon
88 of endothelial cells in the metabolism of 20-hydroxyeicosatetraenoic acid (20-HETE), a vasoactive med
89 (20-COOH-AA) is a bioactive metabolite of 20-hydroxyeicosatetraenoic acid (20-HETE), an eicosanoid th
90 CYP) 4A enzymes catalyze the synthesis of 20-hydroxyeicosatetraenoic acid (20-HETE), an eicosanoid wh
93 450 enzyme to produce the vasoconstrictor 20-hydroxyeicosatetraenoic acid (20-HETE), and that this me
95 a CYPomega-hydroxylase metabolite of AA, 20-hydroxyeicosatetraenoic acid (20-HETE), on the extent of
97 eater than 120-fold higher blood level of 20-hydroxyeicosatetraenoic acid (20-HETE), which correlates
98 e CYP4A enzymes catalyze the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), which has potent
101 arachidonic acid to a mixture of 19- and 20-hydroxyeicosatetraenoic acids (20 and 80% of the total p
102 metabolites of arachidonic acid tested, 5(S)-hydroxyeicosatetraenoic acid (5(S)-HETE) induced DNA syn
103 rease in lipoxygenase (LOX) metabolites 5(S)-hydroxyeicosatetraenoic acid (5-HETE), 8-HETE, and 15-HE
104 with this hypothesis, Erk activation by 5(S)-hydroxyeicosatetraenoic acid (5-HETE; lipoxygenase-indep
105 pid body formation was not LTB4 but was 5(S)-hydroxyeicosatetraenoic acid [5(S)-HETE], which was acti
106 f arachidonic acid, 5(S)-, 12(S)-, and 15(S)-hydroxyeicosatetraenoic acids [5(S)-HETE, 12(S)-HETE, an
107 PV1 (12-hydroperoxyeicosatetraenoic acid, 15-hydroxyeicosatetraenoic acid, 5-hydroxyeicosatetraenoic
109 on and of its arachidonic acid metabolite, 8-hydroxyeicosatetraenoic acid (8-HETE), are highly elevat
111 CYP4F3B converts arachidonic acid to 20-hydroxyeicosatetraenoic acid, a potent activator of prot
112 e oxidizes endogenous arachidonic acid to 20-hydroxyeicosatetraenoic acid, a renal vasoconstrictor an
113 which is converted to the end product 12(S)-hydroxyeicosatetraenoic acid, an eicosanoid that promote
114 c acid to nearly enantiomerically pure 18(R)-hydroxyeicosatetraenoic acid and 14(S), 15(R)-epoxyeicos
115 oncentrations, and that the eicosanoids 8(S)-hydroxyeicosatetraenoic acid and 15-deoxy-Delta12,14-pro
116 ice had 2.5-fold elevations in levels of 12S-hydroxyeicosatetraenoic acid and a 2-fold increase in ex
117 ated with arachidonic acid generated less 12-hydroxyeicosatetraenoic acid and more polar products rel
118 ygenase and cytochrome P450 pathway, such as hydroxyeicosatetraenoic acids and epoxyeicosatrienoic ac
119 ochrome P450s metabolize arachidonic acid to hydroxyeicosatetraenoic acids and epoxyeicosatrienoic ac
120 , whereas CYP2C55 metabolizes AA to EETs and hydroxyeicosatetraenoic acids and linoleic acid to EOAs
121 erivatives such as lipoxins, prostaglandins, hydroxyeicosatetraenoic acids and, most importantly, leu
122 oxygenase metabolites of arachidonic acid, 5-hydroxyeicosatetraenoic acid, and leukotriene B4 in part
123 oic acid, 15-hydroxyeicosatetraenoic acid, 5-hydroxyeicosatetraenoic acid, and leukotriene B4), TRPV4
124 negligible amounts of NPD1, 12(S)- and 15(S)-hydroxyeicosatetraenoic acid, and lipoxin A4 were found
125 through fibronectin was stimulated by 12(S)-hydroxyeicosatetraenoic acid, and this stimulated invasi
126 -associated metabolites prostaglandin E2, 11-hydroxyeicosatetraenoic acid, and thromboxane B2 were id
127 quence variants in the genes that produce 20-hydroxyeicosatetraenoic acid are associated with hyperte
128 hy, the product was identified as >98% 12(R)-hydroxyeicosatetraenoic acid as opposed to the S-stereoi
129 -, and 8, 9-epoxyeicosatrienoic acids and 19-hydroxyeicosatetraenoic acid as the principal reaction p
130 press 12-LOX and synthesize 12(S)- and 15(S)-hydroxyeicosatetraenoic acids as their major LOX metabol
131 io- and stereospecific manner to 16(R)-HETE (hydroxyeicosatetraenoic acid) as the major product.
132 eration of prostaglandin D(2), LTB(4), and 5-hydroxyeicosatetraenoic acid by BMMC from LTC(4)S (-/-)
134 , 9-epoxyeicosatrienoic acids and 11- and 15-hydroxyeicosatetraenoic acids (catalytic turnover, 4.5 n
135 onverts arachidonic acid to 12(S)- and 15(S)-hydroxyeicosatetraenoic acids, causes impaired cell sign
136 f selected lipoxygenases products: 5-,12-,15-hydroxyeicosatetraenoic acid, cysteinyl leukotrienes, le
137 d leukotriene B(4) (LTB(4)) and decreased 5S-hydroxyeicosatetraenoic acid; decreased docosahexaenoic
138 metabotropic glutamate receptors mediate 20-hydroxyeicosatetraenoic acid-dependent vasoconstriction.
139 including the prostaglandins, leukotrienes, hydroxyeicosatetraenoic acids, epoxyeicosatetraenoic aci
140 ases in vitro, forming the novel metabolites hydroxyeicosatetraenoic acid ethanolamides and epoxyeico
141 itors of tyrosine kinase each inhibited 5(S)-hydroxyeicosatetraenoic acid formation by HL-60 cells st
143 tissues may represent a site of localized 15-hydroxyeicosatetraenoic acid generation resulting from c
144 n-treated COX-2 oxygenates 2-AG to afford 15-hydroxyeicosatetraenoic acid glycerol ester in a reactio
145 cies and of the oxidized phospholipid (C18:0/hydroxyeicosatetraenoic acid)-glycerophosphoethanolamine
146 e production and extracellular release of 15-hydroxyeicosatetraenoic acid glyceryl ester (15-HETE-G),
147 nheme cofactor) and its major metabolite 12S-hydroxyeicosatetraenoic acid have been implicated in car
148 d a marked reduction in the production of 11-hydroxyeicosatetraenoic acid (HETE) and 15(S)-HETE, in a
149 B(4), LTE(4), prostaglandin (PG)E(2), and 15-hydroxyeicosatetraenoic acid (HETE) and the mast cell me
150 thrombin stimulates synthesis of 12- and 15-hydroxyeicosatetraenoic acid (HETE) from the released ar
152 cted cells metabolize arachidonic acid to 19-hydroxyeicosatetraenoic acid (HETE) thus CYP2J9 is enzym
153 se products in this regard, since LTD4 and 5-hydroxyeicosatetraenoic acid (HETE) were unable to ampli
155 -oxo-eicosatetraenoic acid, leukotriene B4 5-hydroxyeicosatetraenoic acid (HETE), 12-HETE, and 15-HET
156 was not affected by the LTB4 precursor 5(S)-hydroxyeicosatetraenoic acid (HETE), the omega-oxidation
157 lates the synthesis of the eicosanoid, 12(S)-hydroxyeicosatetraenoic acid (HETE), whereas Sema3A-indu
161 ncrease Ca(2+)-dependent production of toxic hydroxyeicosatetraenoic acids (HETEs) and attenuate the
162 series of signaling molecules, including the hydroxyeicosatetraenoic acids (HETEs) and hydroxyoctadec
163 pholipid hydrolysis is then metabolized into hydroxyeicosatetraenoic acids (HETEs) through lipoxygena
164 ienoic acids (EETs); 5-, 8-, 9-, 12-, and 15-hydroxyeicosatetraenoic acids (HETEs), and 5,6-, 8,15-,
165 hydroperoxyeicosatetraenoic acids (HPETEs), hydroxyeicosatetraenoic acids (HETEs), epoxyeicosatrieno
166 re to UFP significantly increased intestinal hydroxyeicosatetraenoic acids (HETEs), including 15-HETE
167 icosatrienoic acids (EETs) and to 19- and 20-hydroxyeicosatetraenoic acids (HETEs), respectively.
170 the generation of leukotrienes versus 15(S)-hydroxyeicosatetraenoic acid in cells that possess both
171 easing production of the vasoconstrictor, 20-hydroxyeicosatetraenoic acid in the kidney of the Ephx2-
173 pport a role for renal monooxygenases and 20-hydroxyeicosatetraenoic acid in the regulation of BP and
174 he 12/15-lipoxygenase (12/15-LO) product 12S-hydroxyeicosatetraenoic acid increases monocyte adhesion
175 es by cell lysates from prostaglandins to 15-hydroxyeicosatetraenoic acid, indicating the presence of
176 yeicosatrienoic, dihydroxyeicosatrienoic and hydroxyeicosatetraenoic acids influences the biological
177 the following: 1) the 15-LOX2 product, 15(S)-hydroxyeicosatetraenoic acid, inhibits prostate cancer c
178 have potent vasodilatory properties while 20-hydroxyeicosatetraenoic acid is a potent vasoconstrictor
180 landins, thromboxane B(2), leukotriene B(4), hydroxyeicosatetraenoic acid isomers, and arachidonic ac
181 on and secreted substantial amounts of 15(S)-hydroxyeicosatetraenoic acid, its major bioactive lipid
182 the development of hypertension and CKD; 20-hydroxyeicosatetraenoic acid levels are elevated after r
187 egulated (by approximately 60-fold), whereas hydroxyeicosatetraenoic acid metabolites were decreased,
191 e prevents their formation from exogenous 15-hydroxyeicosatetraenoic acid-PE in human monocytes.
193 rface enriched in 12/15-lipoxygenase-derived hydroxyeicosatetraenoic acid-phosphatidylethanolamines.
194 donic acid, oleic acid, linoleic acid, or 20-hydroxyeicosatetraenoic acid, presumably due to competit
196 ase (12-LO, gene ALOX12), which catalyzes 12-hydroxyeicosatetraenoic acid production from arachidonic
198 ression of CYP4A or exogenous addition of 20-hydroxyeicosatetraenoic acid promoted M2 polarization an
200 h LXA(4), but not its metabolic precursor 15-hydroxyeicosatetraenoic acid, reduced expression of VEGF
201 either 14,15-epoxyeicosatrienoic acid nor 19-hydroxyeicosatetraenoic acid significantly improved func
202 in the production of leukotriene B(4) and 5-hydroxyeicosatetraenoic acid, significantly higher than
203 demonstrated that the PPARalpha ligand 8(S)-hydroxyeicosatetraenoic acid strongly promotes the inter
205 Cyp1b1 generated retinoic acid as well as 20-hydroxyeicosatetraenoic acid that regulated P-glycoprote
206 osatrienoic acids and vasoconstrictive 19,20-hydroxyeicosatetraenoic acid, the aim of this study was
208 Phorbol 12-myristate 13-acetate and 12(S)-hydroxyeicosatetraenoic acid, two activators of protein
209 d mediators [lipoxin A4 and 15(S)- and 12(S)-hydroxyeicosatetraenoic acids] under these conditions an
210 ate a 4-fold increase in the formation of 20-hydroxyeicosatetraenoic acid was measured along with a 3
211 a-1 hydroxylase activity (formation of 20/19-hydroxyeicosatetraenoic acid) was detected at 10 weeks a
213 , and 14,15-epoxyeicosatrienoic acids and 20-hydroxyeicosatetraenoic acid when reconstituted with adr
214 lipoxygenase protein and biosynthesize 12(S)-hydroxyeicosatetraenoic acid, which correlates with thei
215 lved remain controversial, especially for 20-hydroxyeicosatetraenoic acid, which has both vasoconstri
216 ites formed via LO, 5(S)-, 12(S)-, and 15(S)-hydroxyeicosatetraenoic acids, which activate p38 MAPK,
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。